EyePoint Pharmaceuticals, Inc. — Director's Dealing 2023

May 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2023-05-25

Reporting Person: Pine Michael Craig (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-05-25	Stock Option (Right to Buy)	$5.93	A	15000.00	Acquired	2033-05-24	Common Stock (15000.00)	Direct
2023-05-25	Restricted Stock Units	$0.00	A	7500.00	Acquired		Common Stock (7500.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.

F2: The restricted stock units will vest in three ratable annual installments beginning May 25, 2024.